Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Krokus Pharma | Geo Medi | Siskhlis Banki | Avalenz | Britanul-Kartuli Satsar… |
|---|---|---|---|---|---|
| Total Revenue | 4,156 | 1,641 | 1,413 | 637 | — |
| Total COGS | -1,741 | -272 | -586 | -280 | — |
| Gross Profit | 2,415 | 1,369 | 827 | 356 | — |
| Gross Margin | 58.1% | 83.4% | 58.5% | 55.9% | — |
| Total Operating Expenses | -998 | -611 | -722 | -312 | — |
| EBITDA | 1,417 | 758 | 104 | 44 | — |
| EBITDA Margin | 34.1% | 46.2% | 7.4% | 6.9% | — |
| Total D&A | -8 | -29 | -85 | -64 | — |
| EBIT / Operating Income | 1,409 | 729 | 19 | -20 | — |
| Total Other Income | -62 | -214 | 80 | -170 | — |
| Profit Before Tax | 1,347 | 526 | 109 | -698 | — |
| Total Income Tax | -74 | -96 | -142 | 0 | — |
| Net Profit / (Loss) | 1,273 | 430 | -33 | -698 | — |
| Net Margin | 30.6% | 26.2% | -2.3% | -109.7% | — |
| Total Interest Income | — | 10 | 10 | 18 | — |
| Total Interest Expense | — | — | — | -525 | — |
Not every picked company reports every selected year — FY2024: no filing for Britanul-Kartuli Satsar…. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Geo Medi | Pharma | 46.2% | 94th pct | 110 |
| Krokus Pharma | Pharma | 34.1% | 83rd pct | 110 |
| Siskhlis Banki | Pharma | 7.4% | 32nd pct | 110 |
| Avalenz | Pharma | 6.9% | 31st pct | 110 |
| Britanul-Kartuli Satsar… | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.